Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 729-736

  Yoshida, Mitsuzi ^a   Matsui, Yuki ^a   Ikarashi, Yoshinori ^a   Usui, Takeo ^b   Osada, Hiroyuki ^b   Wakasugi, Hiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b Japan Science and Technology Agency   (Japan)

Author keywords

tubulin; tubulin; Apoptosis; Caspase 3; mdr1; Mitotic inhibitor; Paclitaxel; Pironetin; Resistant cells; Sub G1; Vindesine

Indexed keywords

ANTIMITOTIC AGENT; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PIRONETIN; UNCLASSIFIED DRUG; VINDESINE;

APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA; LUNG SMALL CELL CANCER; MITOSIS INHIBITION; PRIORITY JOURNAL;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; K562 CELLS; LUNG NEOPLASMS; MITOSIS; PACLITAXEL; PYRONES; VINDESINE;

EID: 34247112846     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kobayshi S, Tsuchiya K, Harada T, Nishide M, Kurokawa T, Nakagawa T, Shimada N and Kobayashi K: Pironetin, a novel plant growth regulator produced by Streptomyces sp. NK10958. I. Taxonomy, production, isolation and preliminary characterization. J Antibiot 47: 697-702, 1994.
2. Usui T, Watanabe H, Nakayama H, Tada Y, Kanoh N, Kondoh M, Asao T, Takio K, Watanabe H, Nishikawa K, Kitahara T and Osada H: The anticancer natural product pironetin selectively targets Lys352 of α-tubulin. Chem Biol 11: 799-806, 2004.
3. Ohta S, Nishio K, Kubo S, Nishio M, Ohmori T, Takahashi T and Saijo N: Characterisation of a vindesine-resistant human small cell lung cancer cell line. Br J Cancer 68: 74-79, 1993.
4. Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T, Nakajima H, Adachi M and Saijo N: Characterization of a taxol-resistant human small cell lung cancer cell line. Jpn J Cancer Res 85: 290-297, 1994.
5. Tsuruo T, Iida-Saito H, Kawabata H, Oh-hara T, Hamada H and Utakoji T: Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn J Cancer Res 77: 682-692, 1986.
6. Yoshida M, Feng W, Saijo N and Ikekawa T: Antitumor activity of daphnane-type diterpene gnidimacrin isolated from Stellera chamaejasme L. Int J Cancer 66: 268-273, 1996.
7. Vindelov LL, Christensen IJ and Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327, 1983.
8. Yoshida M, Feng W, Nishio K, Takahashi M, Heike Y, Saijo N, Wakasugi H and Ikekawa T: Antitumor action of the PKC activator gnidimacrin through cdk2 inhibition. Int J Cancer 94: 348-352, 2001.
9. Kondoh M, Usui T, Kobayashi S, Tsuchiya K, Nishikawa K, Nishikiori T, Mayumi T and Osada H: Cell cycle arrest and antitumor activity of pironetin and its derivatives. Cancer Lett 126: 29-32, 1998.
10. Kondoh M, Usui T, Nishikiori T, Mayumi T and Osada H: Apoptosis induction via microtubule disassembly by an antitumor compound, pironetin. Biochem J 340: 411-416, 1999.
11. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK and Donehower RC: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epiphelial neoplasms. Ann Intern Med 111: 273-279, 1989.
12. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
13. Bunn PA Jr and Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4: 1087-1100, 1998.
14. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T and Thatcher N: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 92: 1074-1080, 2000.
15. Bunn PA Jr, Cullen M, Fukuoka M, Green MR, Hansen HH, Harper P, Johnson D, Klastersky J, Le Chevalier T, Sagman U and Splinter T: Chemotherapy in small cell lung cancer: a consensus report. Lung Cancer 5: 127-134, 1989.
16. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere, A Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P and Tursz T: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367, 1994.
17. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y and Niitani H; Japanese Taxotere Lung Cancer Study Group: Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22: 254-261, 2004.
18. Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP and Meininger V: In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16: 5-8, 1989.
19. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T and Shepherd F: Vinorelbine plus ciplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352: 2589-2597, 2005.
20. Monzo M, RoseII R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY and Martin C: Paclitaxel resistance in non-small cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17: 1786-1793, 1999.
21. Geyp M, Ireland CM and Pittman SM: Increased tubulin acetylation accompanies reversion to stable ploidy in vincristin-resistant CCRF-CEM cells. Cancer Genet Cytogenet 87:116-122, 1996.
22. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW and Hudes GR: Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77: 562-566, 1998.
23. Haber M, Burkhart CA, Regi DL, Madafiglio J, Norris MD and Horwitz SB: Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 270: 31269-31275, 1995.
24. Roy SN and Horwitz SB: A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res 45: 3856-3863, 1985.
25. Juranka PF, Zastawny RL and Ling V: P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3: 2583-2592, 1989.
26. Lowe J, Li H, Downing KH and Nogales E: Refined structure of αβ-tubulin at 3.5 Å resolution. J Mol Biol 313: 1045-1057, 2001.
27. Ravelli RBG, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobei A and Knossow M: Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428: 198-202, 2004.
28. Gigant B, Wang C, Ravelli RBG, Roussi F, Steinmetz MO, Curmi PA, Sobel A and Knossow M: Structural basis for the regulation of tubulin by vinblastine. Nature 435: 519-522, 2005.